SARS-CoV-2 Pneumonia in Hospitalized Asthmatic Patients Did Not Induce Severe Exacerbation.
Adrenergic beta-Agonists
/ therapeutic use
Aged
Asthma
/ drug therapy
Betacoronavirus
COVID-19
Comorbidity
Coronavirus Infections
/ epidemiology
Female
Glucocorticoids
/ therapeutic use
Hospitalization
/ statistics & numerical data
Humans
Intensive Care Units
Male
Middle Aged
Pandemics
Pneumonia, Viral
/ epidemiology
Respiration, Artificial
Retrospective Studies
SARS-CoV-2
Severity of Illness Index
Socioeconomic Factors
Asthma
COVID-19
Coronavirus
Europe
Exacerbation
France
SARS-CoV-2
SARS-CoV-2 pneumonia
Journal
The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
01
05
2020
revised:
11
06
2020
accepted:
12
06
2020
pubmed:
1
7
2020
medline:
18
9
2020
entrez:
1
7
2020
Statut:
ppublish
Résumé
Viral infections are known to exacerbate asthma in adults. Previous studies have found few patients with asthma among severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia cases. However, the relationship between SARS-CoV-2 infection and severe asthma exacerbation is not known. To assess the frequency of asthma exacerbation in patients with asthma hospitalized for SARS-CoV-2 pneumonia and compare symptoms and laboratory and radiological findings in patients with and without asthma with SARS-CoV-2 pneumonia. We included 106 patients between March 4 and April 6, 2020, who were hospitalized in the Chest Diseases Department of Strasbourg University Hospital; 23 had asthma. To assess the patients' asthma status, 3 periods were defined: the last month before the onset of COVID-19 symptoms (p1), prehospitalization (p2), and during hospitalization (p3). Severe asthma exacerbations were defined according to Global INitiative for Asthma guidelines during p1 and p2. During p3, we defined severe asthma deterioration as the onset of breathlessness and wheezing requiring systemic corticosteroids and inhaled β2 agonist. We found no significant difference between patients with and without asthma in terms of severity (length of stay, maximal oxygen flow needed, noninvasive ventilation requirement, and intensive care unit transfer); 52.2% of the patients with asthma had Global INitiative for Asthma step 1 asthma. One patient had a severe exacerbation during p1, 2 patients during p2, and 5 patients were treated with systemic corticosteroids and inhaled β2 agonist during p3. Our results demonstrate that patients with asthma appeared not to be at risk for severe SARS-CoV-2 pneumonia. Moreover, SARS-CoV-2 pneumonia did not induce severe asthma exacerbation.
Sections du résumé
BACKGROUND
BACKGROUND
Viral infections are known to exacerbate asthma in adults. Previous studies have found few patients with asthma among severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia cases. However, the relationship between SARS-CoV-2 infection and severe asthma exacerbation is not known.
OBJECTIVE
OBJECTIVE
To assess the frequency of asthma exacerbation in patients with asthma hospitalized for SARS-CoV-2 pneumonia and compare symptoms and laboratory and radiological findings in patients with and without asthma with SARS-CoV-2 pneumonia.
METHODS
METHODS
We included 106 patients between March 4 and April 6, 2020, who were hospitalized in the Chest Diseases Department of Strasbourg University Hospital; 23 had asthma. To assess the patients' asthma status, 3 periods were defined: the last month before the onset of COVID-19 symptoms (p1), prehospitalization (p2), and during hospitalization (p3). Severe asthma exacerbations were defined according to Global INitiative for Asthma guidelines during p1 and p2. During p3, we defined severe asthma deterioration as the onset of breathlessness and wheezing requiring systemic corticosteroids and inhaled β2 agonist.
RESULTS
RESULTS
We found no significant difference between patients with and without asthma in terms of severity (length of stay, maximal oxygen flow needed, noninvasive ventilation requirement, and intensive care unit transfer); 52.2% of the patients with asthma had Global INitiative for Asthma step 1 asthma. One patient had a severe exacerbation during p1, 2 patients during p2, and 5 patients were treated with systemic corticosteroids and inhaled β2 agonist during p3.
CONCLUSIONS
CONCLUSIONS
Our results demonstrate that patients with asthma appeared not to be at risk for severe SARS-CoV-2 pneumonia. Moreover, SARS-CoV-2 pneumonia did not induce severe asthma exacerbation.
Identifiants
pubmed: 32603901
pii: S2213-2198(20)30667-X
doi: 10.1016/j.jaip.2020.06.032
pmc: PMC7320869
pii:
doi:
Substances chimiques
Adrenergic beta-Agonists
0
Glucocorticoids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2600-2607Informations de copyright
Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Références
Br J Haematol. 2020 Jun;189(6):1044-1049
pubmed: 32330308
Respir Investig. 2020 May;58(3):155-168
pubmed: 32094077
Allergol Int. 2019 Apr;68(2):158-166
pubmed: 30792118
Arch Virol. 2018 Apr;163(4):845-853
pubmed: 29327237
J Allergy Clin Immunol. 2019 Jan;143(1):190-200.e20
pubmed: 30205189
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
N Engl J Med. 2020 Jun 4;382(23):2268-2270
pubmed: 32294339
Eur Respir J. 2002 Jan;19(1):68-75
pubmed: 11852895
Radiology. 2020 Aug;296(2):E32-E40
pubmed: 32101510
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Am J Clin Pathol. 2020 May 5;153(6):725-733
pubmed: 32275742
Am J Respir Crit Care Med. 2020 May 15;201(10):1299-1300
pubmed: 32228035
BMJ. 1993 Oct 16;307(6910):982-6
pubmed: 8241910
BMJ. 1995 May 13;310(6989):1225-9
pubmed: 7767192
FEBS Lett. 2002 Dec 4;532(1-2):107-10
pubmed: 12459472
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Cell Mol Life Sci. 2004 Nov;61(21):2738-43
pubmed: 15549175
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Allergy. 2020 Mar;75(3):576-587
pubmed: 31512243
Eur Respir J. 2016 Jan;47(1):304-19
pubmed: 26677936
Intensive Care Med. 2020 Jun;46(6):1294-1297
pubmed: 32253449
Eur Respir J. 2020 Apr 16;55(4):
pubmed: 32269085
Int J Infect Dis. 2020 Jun;95:183-191
pubmed: 32173576
Lancet Respir Med. 2020 May;8(5):436-438
pubmed: 32251625
Lancet Respir Med. 2015 Nov;3(11):849-58
pubmed: 26493938
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Allergy. 2011 Apr;66(4):458-68
pubmed: 21087215
Rev Mal Respir. 2020 Mar;37(3):243-256
pubmed: 32057505
AJR Am J Roentgenol. 2020 May;214(5):1072-1077
pubmed: 32125873
Sci China Life Sci. 2020 Mar;63(3):457-460
pubmed: 32009228
Allergy. 2020 Jul;75(7):1730-1741
pubmed: 32077115
N Engl J Med. 1990 Oct 11;323(15):1033-9
pubmed: 2215562
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Int J Clin Pract. 2007 May;61(5):725-36
pubmed: 17362472
J Allergy Clin Immunol. 2020 Jul;146(1):203-206.e3
pubmed: 32333915
Invest Radiol. 2020 May;55(5):257-261
pubmed: 32091414
Asian Pac J Allergy Immunol. 2020 Mar;38(1):1-9
pubmed: 32105090